FY2025 Earnings Estimate for Pfizer Inc. (NYSE:PFE) Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Research analysts at Zacks Research upped their FY2025 earnings estimates for shares of Pfizer in a report issued on Wednesday, April 10th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings per share of $2.63 for the year, up from their prior forecast of $2.60. The consensus estimate for Pfizer’s current full-year earnings is $2.22 per share. Zacks Research also issued estimates for Pfizer’s Q4 2025 earnings at $0.74 EPS and FY2026 earnings at $2.64 EPS.

PFE has been the subject of several other research reports. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 1st. Truist Financial dropped their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, UBS Group dropped their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Up 0.1 %

Pfizer stock opened at $26.34 on Thursday. Pfizer has a fifty-two week low of $25.61 and a fifty-two week high of $41.79. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a 50 day moving average price of $27.30 and a 200 day moving average price of $28.98. The company has a market capitalization of $149.12 billion, a PE ratio of 73.15, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the firm earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently modified their holdings of the company. Moneta Group Investment Advisors LLC lifted its position in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares during the last quarter. Norges Bank purchased a new stake in Pfizer in the fourth quarter valued at $2,129,927,000. Wellington Management Group LLP lifted its position in Pfizer by 4.9% in the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after acquiring an additional 11,099,024 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after acquiring an additional 9,393,992 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Pfizer by 13.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after acquiring an additional 8,298,920 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.